Alexion Pharmaceuticals (ALXN) jumped to the top of the S&P 500 today after Barclays upgraded the biotech stock to Overweight from Equal Weight citing fewer macro headwinds.
Shares of Alexion Pharmaceuticals gained 5.2% to $125.59, while the S&P 500 rose 0.1%.
Barclays analyst Geoff Meacham and team explain why they upgraded Alexion Pharmaceuticals:
March has been a month associated with bad news. Remember Julius Caesar and the ides of March? At least Julius had the opportunity to enjoy a couple of good weeks before disaster struck.
Bad news came early in the month for Juno Therapeutics (NASDAQ:JUNO) and PTC Therapeutics (NASDAQ:PTCT). Both companies announced major pipeline setbacks. What’s next for these beleaguered biotechs?
Boring industries and small-capitalization stocks are two things that are very rarely found together. If you search the ranks of the hottest or most promising small-cap stocks, you will find mostly technology and biotech.
So, when I stumbled upon Fuling Global (NASDAQ:FORK), a Chinese manufacturer of plastic cutlery, plates, cups, straws, and similar products, the valuation....More>>>
We presented our long investment thesis on Regeneron (NASDAQ:REGN) to subscribers of our premium Seeking Alpha investment research service, Vasuda Healthcare Analytics, on December 7. Shares rallied about 7% in a week before a pullback. We consider this pullback as another excellent opportunity to start establishing a long position in this blue-chip large-cap biotechnology company.
My Top Pick for speculators for the coming year is a biotech company, explains leading growth and income stock specialist Crista Huff, editor of Cabot Undervalued Stocks Advisor.
Vertex Pharmaceuticals (VRTX) is prominent for its world-leading treatments for cystic fibrosis. Vertex is expected to outperform its peers in earnings growth through 2020.
Vertex is expected to report earnings....More>>>
Investing in biotech and pharmaceuticals is always a bit of a wild card. The industry is often at the mercy of government regulators, and a clinical trial can always present unexpected challenges. When biotech and pharma stocks hit it big, however, its big news that often yields big returns. A lesser promoted biotech sector is the medical devices arena, which is hardly as sexy and....More>>>
Click to enlarge
Sarepta’s hearings. Or how to get a drug approved on emotional grounds. Source: Boston Globe.
In the world of biotech, amazing things sometimes happen. This article is about one such amazing thing: Sarepta’s (NASDAQ:SRPT) twin sister drug, company and stock.
The twin sister, of course, is AveXis (NASDAQ:AVXS). Consider the following:
Some analysts cite Hillary Clinton’s continued criticism of drug prices as a cause for a slump in biotech during the U.S. presidential campaign, but with the election behind us, many biotech enterprises saw at least a 9% increase due to Donald Trump’s victory.
Two companies in the biotech space entering the first quarter of 2017 may be in a position for their products, as well....More>>>
On Thursday, our Elite Opportunity Pronewsletter suggested getting into Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA: LABU) in part totake advantage of the January effect:
As a matter of fact, the entire biotech sector was the big performer yesterday, so we’re going to go ahead and take another shot with LABU, one of the primary bullish leveraged ETF’s tracking the....More>>>
Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:
CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild
Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed....More>>>
ImmunoGen (NASDAQ:IMGN) is up 21.8% at 1:06 p.m. EST on no apparent news. Of course, it’s a biotech, so that’s often par for the course.
One possibility is that day traders are just doing their thing, following the momentum, which pushes the stock price higher. We’ll know in a few days if the share price returns to previous levels.
Welcome to another edition of “3 Things in Biotech You Should Learn Today,” a daily digest dedicated to helping you keep tabs on the fast-moving world of biotech and pharmaceutical research.
Let’s get started!
AstraZeneca whiplash continues with more durvalumab news
In a scrambling defense of disappointing MYSTIC results for its immune checkpoint inhibitor....More>>>
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep up with recent events in the biotech and pharmaceutical industries!
So what’s in store for today?
BioMarin makes itself a priority to the FDA in phenylketonuria
Phenylketonuria is a congenital disorder that can lead to severe complications....More>>>
ImmunoGen (NASDAQ:IMGN) is up 15.6% at 3:35 p.m. EDT on no news. The stock price bump might be a carryover from yesterday’s upgrade by Leerink Partners. Or maybe it’s short-sellers buying to cover their shorts after yesterday’s move. Or maybe it’s just because it’s a biotech and the sun came up today. Who knows?
We are coming into the fall and the third quarter, aftera surprisingly solid push fromthe markets over the summer. Analysts may say it isnt fundamentally sound but that does not detract from the gains. The high valuations, low volatility, no sell in May and go away and even weak economic data and earnings seem immaterial at this point.
The bull market is now over seven years old. Still, the....More>>>